AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 102 min read$COR

Is Cencora Stock Underperforming the Dow?

Cencora (COR), a $61.6B pharmaceutical distributor, is down 14% from its 52-week high but up 18.5% over 3 months, outperforming the Dow. Its Q3 revenue missed estimates, but adjusted EPS beat forecasts. Analysts rate it a 'Strong Buy' with a $366.50 target, implying 12.9% upside. Peer Cardinal Health (CAH) gained 60% over the past year.

Original reporting
yahoo.com
Published Sep 10, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Is Cencora Stock Underperforming the Dow? — source image
Source · yahoo.com
Decision brief

The 30-second read

$CORBullishHigh
01

Why it matters

Earnings beat on EPS and raised guidance may drive short‑term buying, while revenue miss could temper enthusiasm.

02

Market read

First‑report earnings data for a major health‑care distributor, offering actionable insight for traders.

03

What to watch

Potential cost pressures from generic drug pricing and supply chain constraints not discussed.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

Cencora is a $61.6B large‑cap distributor of pharmaceuticals and health‑care products.

Company-level read

Ticker impact

$CORBullishHigh confidence
Context

Cencora reported Q3 2026 earnings with revenue $84.8B (miss) and adjusted EPS $4.48 (beat) and gave FY EPS guidance $17.75‑$17.95, moving the stock up 3.6%.

Expected impact

Potential short‑term upside of 5‑8% as investors price in stronger earnings outlook.

Evidence & confidence

The fresh EPS beat and higher guidance are primary disclosures for a large‑cap distributor, likely prompting immediate trades.

Market effects

Sector

Highlights strength in pharmaceutical distribution sector, may lift peers like Cardinal Health.

Regional

U.S. healthcare distribution market shows resilience amid broader market lag.

Global

Cencora's global footprint suggests modest impact on international supply chains.

Counterpoint

What could challenge this read

Revenue miss could signal underlying demand weakness; caution on over‑reliance on EPS beat.

Key entities

  • Company
    Cencora, Inc.

    Pharmaceutical distributor reporting Q3 2026 results.

Read at source← All news

Related articles

SEP 8
$PGNYMedAI 8/10

Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks

Cencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.

yahoo.com3 min
SEP 6
$CORHighAI 8/10

Why Cencora (COR) Is Getting Attention Today

Cencora (COR) reported Q3 2026 adjusted EPS of $4.48, beating estimates, and raised full-year guidance. Shares fell 1.86% to $330.95 but gained 20.75% over 90 days. The company's long-term returns are strong, with a 1-year return of 14.01% and a 5-year return of 183.23%. Analysts suggest fair value at $372.58, citing digital investments and healthcare trends.

simplywall.st2 min
AUG 23
$MCKMedAI 8/10

and Getting Worse. Here Are 2 Stocks That Turn Rising Prices Into Rising Profits.

McKesson (MCK) and Cencora (COR) are positioned to benefit from certain drug price inflation due to contractual provisions. McKesson reported $403.4B revenue and $39.11 EPS for fiscal 2026, with Q1 2027 revenue at $105.4B and EPS at $9.93. Cencora generated $321.3B revenue in fiscal 2025, with Q2 revenue at $78.4B and EPS at $4.75. Both companies have raised EPS forecasts.

aol.com3 min
AUG 21
$MCKHighAI 9/10

With Price-Increase Clauses, These Two Drug Distributors Can Withstand ‘Trumpflation’

McKesson (MCK) and Cencora (COR) benefit from drug price increases due to inflation-based compensation clauses. McKesson reported $403.4B revenue in 2026, up 12%, and raised EPS guidance. Cencora posted $321.3B revenue in 2025, up 3.8%, and increased EPS guidance. Both companies' contracts allow gains from manufacturer price hikes, but risks include regulation and cost pressures.

nai500.com3 min
AUG 20
$CVSMedAI 8/10

Health Insurance Providers Stocks Q2 Teardown: Clover Health (NASDAQ:CLOV) Vs The Rest

CVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. Despite strong earnings, its stock fell 10.2% to $93.76. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, causing a 15.3% stock drop to $25.58. Cencora (COR) reported $84.75B revenue, up 5.1% YoY, in line with expectations, with a 3.2% stock increase to $316.20. UnitedHealth (UNH) reported $112B revenue, flat YoY, beating estimates, but its stock fell 7.1% to $388.62.

finance.yahoo.com3 min